Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Settles Adderall XR Patent Case With Impax, But Remains At Impasse With Barr

This article was originally published in The Pink Sheet Daily

Executive Summary

If a generic amphetamine extended-release launches before 2010, Impax will sell Shire’s authorized generic.

You may also be interested in...



Vyvanse Adds 14-Hour Duration Data As Shire's ADHD Drugs Face Off With Generics

Duration of use data will help to strengthen Vyvanse's position in the fast-growing adult segment, Shire says.

Vyvanse Adds 14-Hour Duration Data As Shire's ADHD Drugs Face Off With Generics

Duration of use data will help to strengthen Vyvanse's position in the fast-growing adult segment, Shire says.

Shire Patent Infringement Suit Over Adderall XR Triggers 30-Month Stay

Stay of FDA action on Andrx' ANDA will extend beyond Barr's entry, Shire says.

Related Content

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel